Posted by Michael Wonder on 06 Oct 2020
PixCell Medical announces regulatory approval from Australian TGA for HemoScreen point of care hematology analyser
5 October 2020 - PixCell Medical announced today that it has received regulatory approval from the Australian TGA for the HemoScreen, PixCell's hematology analyser that offers a 5 part differential complete blood count intended for point of care use.
Under the TGA approval, PixCell's HemoScreen is cleared for use with adults and infants alike, from as early as 2 months of age.
The HemoScreen provides insights on 20 complete blood count parameters as well as comprehensive abnormal cell flagging, which can assist in the early detection of diseases, including several types of cancer.
